Adamis Pharmaceuticals Corporation (ADMP)
ADMP Stock Price Chart
Key Info
| Market Cap | 44.18M |
| Revenue (ttm) | 18.43M |
| Net Income (ttm) | -34.71M |
| Shares Out | 76.04M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $0.472 |
| Previous Close | $0.472 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.470 - 0.500 |
| Day's Volume | 298,495 |
| 52-Week Range | 0.327 - 1.450 |
ADMP Stock News
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th...
Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript
Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a b...
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, ...
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...
SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was in...
Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript
Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provid...
SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) fil...
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting A...
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of co...
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license to commercialize Tempol, a novel patented investigation...
Adamis recently reported their Q1 earnings with a miss on EPS and revenue. The COVID-19 pandemic has had a significant impact on the company's US Compounding sales.
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a busi...
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) I...
Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Int...
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ha...
Adamis Pharmaceuticals: Trying To Find A Course Of Action
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Payc...
SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ...
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement...
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...
SAN DIEGO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of ...
Adamis Pharmaceuticals Corp (ADMP) CEO Dennis Carlo on Q3 2019 Results - Earnings Call Transcript
Adamis: Overdue ZIMHI Decision Puts The Brakes On Stock's Downward Trend
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received an...
Adamis Pharmaceuticals and its investors are preparing for ZIMHI's PDUFA on October 31st. I provide a brief background on ZIMHI and recap its journey thus far.
SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high do...
Adamis recently secured a Australian and New Zealand partnership for SYMJEPI. Although this was a positive move for the company, the market responded negatively with a new 52-week low.
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agre...
Adamis recently updated investors on the progress made in the launch of SYMJEPI and SYMJEPI Jr. Unfortunately, the market wasn't impressed and the stock hit another 52-week low.
SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinep...
SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors.
Adamis recently reported a mixed Q2 earnings with a beat on EPS and a miss on revenue. I review the earnings report and the company's conference call.
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q2 2019 Results - Earnings Call Transcript
Adamis has settled their patent and trademark legal battles with kaléo Inc. Now, Adamis can focus on finding a commercial partner for their ZIMHI product candidate before the October PDUFA.
Sandoz recently announced the U.S.retail launch of SYMJEPI in the middle of a Epipen shortage around the country.
Adamis has been a tortuous investment for most shareholders due to a never-ending devaluation of their investment. However, it appears the market has created a deep discount.
Adamis recently announced their Q1 earnings and reported a slight miss on EPS and revenue. However, it was the company's announcement that they cut Op-Ex in order to prevent an offering.
About ADMP
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Dennis Carlo | Employees 131 |
| Stock Exchange NASDAQ | Ticker Symbol ADMP |
Financial Performance
In 2019, ADMP's revenue was $22.11 million, an increase of 46.58% compared to the previous year's $15.09 million. Losses were -$29.31 million, -24.87% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is an increase of 112.00% from the latest price.